Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort
Annals of Rheumatic Diseases, 05/11/2012
Gottenberg JE et al. – Serum IL–6 concentration is greater in rheumatoid arthritis (RA) than in undifferentiated arthritis (UA). Increase in serum IL–6 and IL–21 levels is associated with markers of B cell activation, and IL–6 is associated with radiographic progression in patients with RA.
Serum interleukin (IL)–1β, IL–1 receptor antagonist (IL1–Ra), IL–2, IL–4, IL–6, IL–10, IL–17, IL–21, monocyte chemotactic protein 1 (MCP–1), tumour necrosis factor α and interferon γ levels were measured in the (ESPOIR) Etude et Suivi des POlyarthrites Indifférenciées Récentes early arthritis cohort, which included patients with at least two swollen joints for >6 weeks and <6 months, and no previous corticosteroids or disease–modifying antirheumatic drugs.
Serum cytokine levels were compared between patients who met the 1987 American College of Rheumatology criteria for RA (n=578) or had undifferentiated arthritis (UA, n=132) at the 1–year follow–up visit.
Serum IL–6 and IL–21 were the only cytokines that discriminated RA from UA on univariate analysis. IL–6 level was associated with RA, whereas erythrocyte sedimentation rate and C–reactive protein were not.
Higher proportions of rheumatoid factor and anticyclic citrullinated protein (CCP) positivity, levels of markers of B cell activation, and a higher frequency of rapid radiographic progression were observed in patients with RA with detectable IL–6 or IL–21.
Multivariate analysis associated IL–6 and anti–CCP levels with radiographic erosions at enrolment with 1–year radiographic progression.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.